Yangzhou, China

Fanzeng Meng

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Yangzhou University. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Fanzeng Meng. Retrieved from https://idiyas.com/inventor/fanzeng-meng

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Fanzeng Meng: Innovator in Monoclonal Antibody Research

Introduction

Fanzeng Meng is a prominent inventor based in Yangzhou, China. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His innovative work has led to the creation of a patented hybridoma cell line that has important applications in medical research.

Latest Patents

Fanzeng Meng holds a patent for a hybridoma cell line secreting an ActA monoclonal antibody and its use. This patent represents a crucial advancement in the production of monoclonal antibodies, which are essential tools in diagnostics and therapeutics.

Career Highlights

Fanzeng Meng is affiliated with Yangzhou University, where he conducts research and contributes to the academic community. His work at the university has allowed him to explore various aspects of biotechnology and to mentor aspiring scientists in the field.

Collaborations

Throughout his career, Fanzeng Meng has collaborated with notable colleagues, including Dan Gu and Jinlin Huang. These collaborations have fostered a productive research environment and have led to further advancements in their shared field of study.

Conclusion

Fanzeng Meng's contributions to monoclonal antibody research exemplify the impact of innovative thinking in biotechnology. His work continues to influence the development of new medical therapies and diagnostic tools.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…